Forteoteriparatide
According to the FDA label: Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide injection reduces the risk of vertebral and nonvertebral fractures.
111,630 adverse event reports submitted to the FDA (2004–2026)
Top Reported Adverse Events
The most frequently reported events in association with Forteo in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
Nausea 8,983 reports
The feeling of sickness in your stomach that often comes before vomiting.
Full definition in the glossary → See all drugs reporting this event →Arthralgia 8,672 reports
Pain in Extremity 8,349 reports
Pain in an arm or leg.
Full definition in the glossary →Dizziness 8,285 reports
A feeling of being lightheaded, unsteady, or like the room is spinning.
Full definition in the glossary → See all drugs reporting this event →Fall 7,893 reports
A report that the person fell down. Falls are tracked because they can signal issues like dizziness, weakness, or balance problems.
Full definition in the glossary →Pain 7,531 reports
A general report of physical discomfort, used when no more specific location is given.
Full definition in the glossary →Fatigue 7,180 reports
Extreme tiredness or lack of energy that does not improve with rest.
Full definition in the glossary → See all drugs reporting this event →Back Pain 5,917 reports
Muscle Spasms 5,738 reports
Sudden, involuntary tightening of a muscle, often called cramps.
Full definition in the glossary → See all drugs reporting this event →Malaise 5,666 reports
A general feeling of being unwell or uncomfortable, without a specific symptom.
Full definition in the glossary →Headache 5,476 reports
Pain in the head or upper neck.
Full definition in the glossary → See all drugs reporting this event →Asthenia 5,435 reports
Physical weakness or lack of strength.
Full definition in the glossary →Injection Site Erythema 5,052 reports
Redness of the skin at the spot where a medication was injected. Erythema means skin redness.
Full definition in the glossary →Injection Site Pain 4,815 reports
Pain at the spot on the body where a medication was injected.
Full definition in the glossary →Injection Site Bruising 4,768 reports
Bruising at the spot where a medication was injected.
Full definition in the glossary →
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Female | 99,663 |
| Male | 10,286 |
| Unknown | 40 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 63 |
| 18-34 | 339 |
| 35-49 | 1,872 |
| 50-64 | 14,735 |
| 65-74 | 18,128 |
| 75+ | 25,193 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Forteo. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Non-Serious | 70,217 |
| Hospitalization | 24,098 |
| Other Serious | 21,270 |
| Death | 5,283 |
| Disability | 864 |
| Life-Threatening | 688 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Forteo. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2004 | 6,414 |
| 2005 | 4,792 |
| 2006 | 2,194 |
| 2007 | 2,193 |
| 2008 | 2,133 |
| 2009 | 3,068 |
| 2010 | 3,799 |
| 2011 | 5,405 |
| 2012 | 6,251 |
| 2013 | 2,648 |
| 2014 | 1,297 |
| 2015 | 44,975 |
| 2016 | 2,140 |
| 2017 | 4,040 |
| 2018 | 4,898 |
| 2019 | 4,008 |
| 2020 | 1,955 |
| 2021 | 1,813 |
| 2022 | 1,582 |
| 2023 | 1,756 |
| 2024 | 1,839 |
| 2025 | 2,081 |
| 2026 (partial) | 349 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Medications commonly reported with Forteo
In FDA adverse event reports that mention Forteo, these medications appeared most often in the same report.
- Ergocalciferol (6,042 reports)
- Levothyroxine (3,321 reports)
- Aspirin (3,180 reports)
- Prednisone (2,625 reports)
- Omeprazole (2,426 reports)
This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026